Genmab — Februar 2019
-
hmm - clinicaltrials siger 100 pts
-
my bad - det var det oprindelige fase I/II studie der var på 55 cervical pts
-
er der nogen bud på threshold på den ORR, der skal til for at lave ansøgning? på det behandlede antal patienter lyder det til at det bliver cervical
-
-
it does say "potentially pivotal" in all press releases
-
det er bare sjældent at se responsraterne holde niveauet, når man udvider populationen…
-
God morgen
-
Sounds good to me. 1st line treatment should be the target. 3rd and 4th line ıf fine but ıf ıts increase survival 5 month only then ıt might be hard to get governments to pay millions for the additional few month. However 1st line will be knock your socks off material. Wipe out all the competitors.
-
Copenhagen, Denmark, February 12, 2019
DARZALEX split dosing regimen approved by U.S. FDA
Provides healthcare professionals with option to split first DARZALEX infusion over two consecutive days
Approval supported by data from EQUULEUS (MMY1001) clinical trial
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind